MarginsXMarginsX
Home › Markets › Health Care › NBIX

Neurocrine Biosciences Inc. (NBIX)

NBIX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$165.31
-1.25% on the day
Market cap
$16.7B
Large cap
Revenue · 2025
$2.9B
+21.4% on 2024
Net income · 2025
$478.6M
16.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/0000914475-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNBIX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1996
SEC CIK0000914475
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.9B
Net income$478.6M
Operating income$619.1M
Net margin16.7%
Operating margin21.6%
Revenue growth+21.4%
Cash$713.0M
Total assets$4.6B
P/E (computed)35.0×
P/S (computed)5.8×

Warning signs

Cash runway
Cash-flow positive
$641.5M cash at September 30, 2026
Share count, 1 year
+1.5%
2025-10-21 to 2026-10-26 · +3.0% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$77.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$641.5M cash; operating cash flow $266.4M a quarter.Report 2026-09-30
Shares outstanding101,218,643 (2026-10-26); 99,705,698 a year earlier; 98,251,923 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $77.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.1B$206.5M$395.2M$641.5MNo debt tags$3.7B10-Q 2026-11-02
Q2 2026
2026-06-30
$959.0M$144.4M$136.4M$332.4MNo debt tags$3.4B10-Q 2026-07-31
Q1 2026
2026-03-31
$814.5M$197.9M$145.8M$266.5MNo debt tags$3.1B10-Q 2026-05-05
Q4 2025
2025-12-31
$805.5M$153.7M$388.4M$713.0MNo debt tags$2.9B10-K 2026-02-11
Q3 2025
2025-09-30
$794.9M$209.5M$227.5M$340.2MNo debt tags$2.7B10-Q 2026-11-02
Q2 2025
2025-06-30
$687.5M$107.5M$102.0M$264.0MNo debt tags$2.5B10-Q 2026-07-31
Q1 2025
2025-03-31
$572.6M$7.9M$64.8M$194.1MNo debt tags$2.4B10-Q 2026-05-05
Q4 2024
2024-12-31
$627.7M$103.1M$242.5M$233.0M$0$2.4B10-K 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-11
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-15

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.7%
1 month+23.9%
3 months+11.0%
Year to date+18.0%
1 year+16.1%
From 52-week high-9.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
EXELExelixis Inc.$67.10-2.75%$16.4B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
TECHBio-Techne Corp$72.79-0.01%$11.4B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
RGENRepligen Corporation$162.78-2.99%$10.4B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier